naproxen

(redirected from Vimovo)
Also found in: Dictionary, Thesaurus, Encyclopedia.

naproxen

 [nah-prok´sen]
a nonsteroidal antiinflammatory drug that is a propionic acid derivative with analgesic, antipyretic, and antiinflammatory activity; used for treatment of rheumatoid arthritis, osteoarthritis, gout, calcium pyrophosphate deposition disease, fever, and dysmenorrhea, and in the prophylaxis and suppression of vascular headache; administered orally or rectally, as the base or the sodium salt.

naproxen

/na·prox·en/ (nah-prok´sen) a nonsteroidal anti-inflammatory drug used as the base or the sodium salt in the treatment of pain, inflammation, arthritis, gout, calcium pyrophosphate deposition disease, fever, and dysmenorrhea and in the prophylaxis and suppression of vascular headache.

naproxen

(nə-prŏk′sən)
n.
A nonsteroidal anti-inflammatory drug, C14H14O3, used to treat fever and pain.

naproxen

[naprok′sən]
a nonsteroidal antiinflammatory agent.
indications It is prescribed for the relief of fever, migraine headache, inflammatory symptoms of rheumatoid arthritis and osteoarthritis, and mild to moderate pain and for treatment of primary dysmenorrhea, ankylosing spondylitis, tendinitis, bursitis, and acute gout.
contraindications Impaired renal function, GI disease, or known hypersensitivity to this drug, to aspirin, or to nonsteroidal antiinflammatory drugs prohibits its use.
adverse effects Among the more serious adverse effects are GI disorders and peptic ulcers. Dizziness, rashes, and tinnitus commonly occur. This drug interacts with many other drugs.

naproxen

Naprosyn® Therapeutics An oral NSAID excreted through the kidney, breast milk, which crosses the placental barrier. See NSAIDs.

naproxen

A NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID). Brand names are Naprosyn, Nycopren, Synflex and, formulated with the prostaglandin drug MISOPROSTOL, Napratec.

naproxen

non-steroidal anti-inflammatory drug used to control pain and inflammation in rheumatoid disease, musculoskeletal disorders and acute gout

naproxen

a propionic acid derivative with analgesic, antipyretic and anti-inflammatory activity (a nonsteroidal anti-inflammatory agent); its use is associated with gastroduodenal ulceration in dogs.
References in periodicals archive ?
Like all medications that contain nonsteroidal anti-inflammatory drugs (NSAIDs), VIMOVO may increase the chance of a heart attack or stroke that can lead to death.
NSAID-containing medications, such as VIMOVO, should never be used before or after a type of heart surgery called coronary artery bypass graft (CABG)
As with all medications that contain NSAIDs, VIMOVO may increase the chance of stomach and intestinal problems, such as bleeding or an ulcer, which can occur without warning and may cause death
VIMOVO is not right for everyone, including patients who have had an asthma attack, hives, or other allergic reaction with aspirin or any other NSAID medicine, patients who are allergic to any of the ingredients in VIMOVO, or women in late stages of pregnancy.
Serious allergic reactions, including skin reactions, can occur without warning and can be life-threatening; discontinue use of VIMOVO at the first appearance of a skin rash, or if you develop sudden wheezing; swelling of the lips, tongue or throat; fainting; or problems swallowing.
Speak with your health care provider before starting VIMOVO if you
Naproxen, a component of VIMOVO, may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal.
VIMOVO is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
NSAIDs, including naproxen, a component of VIMOVO, cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.
VIMOVO is contraindicated in patients with known hypersensitivity to any component of VIMOVO or substituted benzimidazoles; in patients with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; in patients during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery; or in patients in the late stages of pregnancy.
As with all NSAIDs, VIMOVO can lead to the onset of new hypertension or worsening of pre-existing hypertension, either of which may contribute to the increased incidence of CV events.
Fluid retention and edema have been observed in some patients taking NSAIDs, including VIMOVO.